Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionovo has reported positive results from two independent physician surveys, which showed that MF101 could become first-line treatment for menopausal vasomotor symptoms or hot flashes.
Subscribe to our email newsletter
In both qualitative and quantitative studies, 124 physicians board certified in obstetrics, gynecology and specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes. In addition, 92% of physicians reported they would prescribe MF101 before prescribing an antidepressant agent for hot flashes.
Isaac Cohen, chairman and CEO of Bionovo, said: “These independent physician studies provide us with further evidence that if available, MF101 can be a blockbuster drug once it hits the market.”